Irbesartan/Hydrocholorthiazide Teva (Hydrochlorothiazide, Irbesartan)

Irbesartan blocks the AT1 receptor for angiotensin II, preventing the hormone from causing blood‑vessel constriction and aldosterone release. This leads to relaxed vessels and reduced blood volume. When paired with hydrochlorothiazide, which increases urine output, the overall effect is a synergistic reduction in blood pressure.

The specific dose of Irbesartan/Hydrochlorothiazide is determined by the prescribing clinician based on the patient’s blood‑pressure readings, kidney function, and other health factors. The prescriber will select the appropriate strength and dosing schedule that best fits the individual’s therapeutic needs.

Safety of Irbesartan/Hydrochlorothiazide in pregnancy or while breastfeeding has not been established. It is generally avoided during pregnancy, especially in the second and third trimesters, because of potential risks to the fetus. Women who are breastfeeding should consult their healthcare provider before using this medication.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details and any necessary import documentation.

Compared with single‑agent therapy, the fixed‑dose combination offers the convenience of one tablet and the additive effect of two mechanisms—angiotensin II blockade and diuresis. This can improve adherence and achieve target blood‑pressure levels more efficiently than using an ARB or a thiazide alone, especially in patients requiring both actions.

Store the tablets at room temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the container tightly closed and out of reach of children. Do not store in humid or excessively hot environments, as this may affect tablet integrity.

The medication is taken orally, usually once daily, with or without food, as directed by the prescriber. Swallow the tablet whole with a full glass of water. Do not crush, split, or chew the tablet unless the prescriber specifically advises otherwise.

Serious risks include severe dehydration, significant electrolyte disturbances (especially low potassium), acute kidney injury, marked hypotension, and rare cases of angioedema. Patients should report symptoms such as sudden dizziness, swelling of the face or throat, rapid weight loss, or muscle weakness to their healthcare provider promptly.

The combination should be avoided in individuals with known hypersensitivity to irbesartan, hydrochlorothiazide, or any component of the formulation. It is also contraindicated in patients with severe renal impairment, anuria, or severe electrolyte imbalance, and in those with a history of angioedema related to ARB therapy.